Cardiology Practice Review: Issue 31, with commentary by Dr Janette Tenne

In this issue:

–  2023 ESC cardiomyopathy guidelines
–  Exercise and physical activity in cardiac rehabilitation
–  Focused update of ESC heart failure guidelines
–  2023 ESC guidelines for patients with CVD and diabetes
–  Screening for hypertensive disorders of pregnancy
–  CVD in women
–  60-day prescriptions of PBS medicines
–  Statin intolerance: An overview of US and international guidance
–  Cuff size affects the accuracy of BP readings
–  Shared decision-making in international CV guidelines
–  Temperature management for comatose adult survivors of cardiac arrest
–  COVID-19 resources
–  Conferences, workshops and CPD

Download Cardiology_Practice_Review_Issue_31 here (pdf) 

*NEW* Heart Failure Practice Review Issue 1, with commentary by Prof Andrew Coats

A new Practice Review for Heart Failure, with commentary by Prof Andrew Coats.  

Look forward to updates and new treatment guidelines, changes to medicines reimbursement and licensing, educational and professional body news plus plus  our COVID-19 resources for Cardiologists. This issue:

–  Focused update of ESC HF guidelines
–  CPP for avoiding and mitigating HF
–  Managing HFpEF
–  Safety and efficacy of empagliflozin in patients with HFpEF using diuretics
–  Comparison of current HF international guidelines
–  Cardio-obstetrics and HF
–  60-day prescriptions of PBS medicines
–  Semaglutide improves HF and CVD
–  Complete revascularisation impact on HF in patients with ACS and MVD
–  Sex-based differences in acute HF treatment and outcomes
–  COVID-19 resources
–  Conferences, workshops and CPD

Download the Heart Failure Practice_Review_Issue_1

CSANZ Members – Sports Cardiology Working Group

Welcome to the CSANZ Sports Cardiology Working Group

In 2021 CSANZ formed a working group for Sports Cardiology due to the increased demand for training and a dedicated service provision for this niche field, whilst also providing a forum for discussing interesting cases and progress within Sports Cardiology.  

Read more about the emerging subspecialty Sports Cardiology here

BENEFITS OF BEING PART OF THE CARDIOLOGY WORKING GROUP:
  • Invitation to the Sports Cardiology Working Group Meeting at the CSANZ ASM.
  • Access to collaborative research opportunities.
  • Access to educational and networking events.
  • Be part of the grass roots of a new subsection of cardiology in Australasia.
CSANZ ASM 2023
HOW TO JOIN THE WORKING GROUP

 (current CSANZ membership is essential)

As we build our profile of experts, we invite you to contact us on [email protected] if you have an interest in research opportunities, collaborations, education or training in the field, attending events and  building a valuable resource for those working in sports cardiology.

It’s very easy to join the Sports Cardiology Working Group, contact us by email with your name and contact details and subject: Join the Sports Cardiology Working Group and send it to [email protected].

UPCOMING EVENTS
1 – 3 March 2024
International Sudden Cardiac Arrest and Sports Symposium, Lorne, VIC

Details to follow soon.

8 -10 May 2024
International Clinical Cardiovascular Genetics Conference 2024, Brisbane, QLD (ICCG 2024)

Calling for Abstracts           Read more

The closing date for abstract submission is 28 February 2024.

SPECIALISED CLINICS

We have developed dedicated specialised sports cardiology services in Melbourne (St Vincent’s Hospital) and Sydney (RPAH) and are aware of several specialists around Australia and New Zealand who have a dedicated interest and expertise. If you wish to refer a patient to our dedicated subspecialized sports cardiology clinics the contact details are below:

SPORTS CARDIOLOGY FOCUS OF THE MONTH
We would love to see you sharing an ECG, image or interesting case in this section, please email your images to: [email protected] with Sports Cardiology Focus of the Month in the subject line.
LATEST JOURNAL ARTICLES

Clinical outcomes of 10 years of cardiac screening in elite New Zealand athletes
Journal of Science and Medicine in Sport 

Author:  Jessica J. Orchard et al
 
CURRENT GUIDELINES OF SPORTS CARDIOLOGY
PERFORMANCE MEASURES AND OTHERS
POSITION STATEMENTS AND CONSENSUS DOCUMENTS
OTHER PUBLICATIONS

Link to other Articles in European Heart Journal (EHJ)                Link to other articles in the JACC Journal  

OTHER RESOURCES

Links to International Sports Cardiology website resources:

Cardiology Research Review: Issue 157, with commentary by A/Prof John Amerena

In this Issue:

  • Cardiovascular safety of testosterone replacement therapy
  • The FGF21 analogue pegozafermin for severe hypertriglyceridaemia
  • Zilebesiran, an RNA interference therapeutic agent for hypertension
  • Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid
  • Atorvastatin for anthracycline-associated cardiac dysfunction
  • Mortality trends after primary PCI for STEMI in Denmark
  • Cost-effectiveness of vericiguat in patients with HFrEF
  • Mineralocorticoid receptor antagonists are underutilised in patients with HFrEF
  • Phenotyping coronary plaque in patients with premature coronary artery disease
  • Stroke risk in women with AF

Download the Cardiology_Research_Review_Issue_157 (pdf) 

PhD opportunities – Westmead Applied Research Centre, Sydney, NSW

Position : Exciting PhD or Masters Opportunity at The University of Sydney and Westmead Hospital for 2024

Spontaneous Coronary Artery Dissection (SCAD) is increasingly recognised as an important cause of myocardial infarction (MI). Global estimates suggest SCAD is the most common cause of MI in women under the age of 50. Yet very little is known about the best way to prevent, diagnose and treat SCAD. The Australian New Zealand SCAD (ANZ-SCAD) Registry is being led by Associate Professor Sarah Zaman out of the Westmead Applied Research Centre (WARC) at the University of Sydney and Westmead Hospital. This national effort will recruit patients with SCAD from more than 22 hospitals across Australia and New Zealand. Data pooling with national and international SCAD cohorts will enable important research questions to be answered.

Applications are open for a PhD candidate to join the team of SCAD researchers, under the supervision of A/Prof Sarah Zaman. They will be joining the academic team at WARC, led by Director Professor Clara Chow. The research team has extensive experience in leading grants, publications, and supporting students to win awards and scholarships. Ideal applicants will have a medical degree and clinical cardiology training. To apply (or for further details), please send your CV to [email protected]. An ideal candidate would have experience in coronary angiography interpretation. To determine your eligibility for a PhD or Masters at the Faculty of Medicine and Health please visit this link.

To learn more about our centre at WARC, visit this link.

Position : PhD or Masters Opportunity in Myocardial Infarction in the Young

Myocardial infarction (MI) in young people (< age 50 years) is a devastating event that can have significant mortality, morbidity, psychological and financial effects for the individual and their families. Applications are open for a PhD or Masters candidate to join Associate Professor Sarah Zaman, and the team to research heart attacks in the young. A Young MI Registry has already begun (ethics and governance approval in place) at Westmead Hospital, Western Sydney, NSW, recruiting patients both historically and prospectively. Biomarkers, such as lipids, diabetic markers, lipoprotein(a) and high sensitivity CRP are collected. Dietary and exercise surveys are completed by prospectively consented participants. Research will focus on the different presentation features, outcomes and medical therapy as well as sex and ethnic differences and gaps in care, between young and older people with MI. Opportunity may arise to conduct prospectively clinical trials in consented participants and their families.

A PhD or master student would be joining the academic team at the Westmead Applied Research Centre, an Impact Centre of the Faculty of Medicine and Health, at the University of Sydney, under the directorship of Director Professor Clara Chow. The research team has extensive experience in leading grants, publications, and supporting students to win awards and scholarships. Ideal applicants will have clinical experience in cardiovascular disease. To apply (or for further details), please send your CV to [email protected]. Please first determine your eligibility for a PhD or Masters at the Faculty of Medicine and Health please visit this link.

To learn more about our centre at WARC, visit this link.

Position : PhD or Masters Opportunity in Diet and Heart Failure

Heart failure with reduced ejection fraction is the leading cause of hospitalisation worldwide and affects ~64 million people globally. The failing heart has been found to use ketone bodies as a significant source of energy, resulting in improvements in heart function. This has led to a theoretical basis for a benefit of ketosis in heart failure, yet clinical research in this area (such as application of a ketogenic diet) is lacking. In fact, there are incredibly few dietary trials of any kind specific to patients with heart failure, despite diet being a cornerstone of heart disease prevention and treatment.

Applications are open for a PhD or Masters candidate to join the team to research dietary interventions in treatment of patients with heart failure, under the supervision of A/Prof Sarah Zaman. They will be joining the academic team at the Westmead Applied Research Centre, an Impact Centre of the Faculty of Medicine and Health, at the University of Sydney, led by Director Professor Clara Chow. Research projects will focus on diet and heart failure, including utilisation of available longitudinal data, systematic reviews and involvement in a grant-funded prospective clinical trial of a dietary intervention in patients with heart failure. The research team has extensive experience in leading grants, publications, and supporting students to win awards and scholarships. Ideal applicants will have clinical experience in heart failure and/or in application of diet to prevent chronic disease. To apply (or for further details), please send your CV to [email protected]. To determine your eligibility for a PhD or Masters at the Faculty of Medicine and Health please visit this link.

To learn more about our centre at WARC, visit this link.

Heart Failure Research Review: Issue 79, with commentary by Prof Andrew Coats

In this edition:

–  Remote pulmonary artery pressure monitoring in chronic HF
–  CTS associated with subsequent HF
–  RAS inhibition and outcomes in HFREF and advanced kidney disease
–  CRP and incident HF risk in patients with CV disease
–  LBBAP vs. BVP in CRT candidates
–  Torsemide vs. furosemide in hospitalised HF: symptoms and QOL
–  Anaemia: effect of sacubitril-valsartan
–  Neurohormonal antagonist initiation after HF hospitalisation in older adults
–  Predictors of long-term CV and non-CV mortality in HFPEF
–  HF pharmacotherapies and outcomes in obese vs. nonobese HFREF patients

Download the Heart Failure Research Review: Issue 79, with commentary by Prof Andrew Coats (pdf)

Cardiology Research Review: Issue 156, with commentary by A/Prof John Amerena

In this issue:

  • Self-administered intranasal etripamil for paroxysmal SVT
  • Vitamin D supplementation does not have cardioprotective effects
  • Barriers to prescribing PCSK9 inhibitors after coronary revascularisation
  • Ferric carboxymaltose in patients with HF and iron deficiency
  • Semaglutide in patients with obesity-related HFpEF
  • Are anticoagulants justified in patients with atrial high-rate episodes?
  • Should frail elderly patients who are taking warfarin be switched to a NOAC?
  • Phase 1 trial of muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation
  • Catheter ablation vs medical therapy for AF in end-stage HF
  • Multivessel immediate vs staged revascularisation in acute STEMI

Download the Cardiology Research Review Issue 156 with commentary by A/Prof John Amerena (pdf) here

Abbott: GALLANT™, NEUTRINO™ NXT, and ENTRANT™ ICDs and CRT-Ds manufactured prior to April 2022 (August 2023)

Bluetooth circuit component issue which can:
1. disable Bluetooth telemetry (including remote monitoring) and,
2.result in high current consumption leading to reduced device longevity.

ANZCDACC Management Recommendations for Abbott Product Defect Correction
August 2023

Download PDF

Device:
GALLANT™, NEUTRINO™ NXT, and ENTRANT™ ICDs and CRT-Ds manufactured prior to April 2022
(Models CDVRA500Q, CDDRA500Q, CDHFA500Q, CDVRA600Q, CDDRA600Q, CDHFA600Q, CDVRA300Q, CDDRA300Q and CDHFA300Q)
Note: No affected NEUTRINO™ NXT or ENTRANT™ ICDs and CRT-Ds were implanted in Australia.
No affected GALLANT™ or NEUTRINO™ NXT ICDs and CRT-Ds were implanted in NZ.

TGA Reference:
RC-2023-RN-00734-1

 

 

Posts navigation